SCHEMBL25472686

SCHEMBL25472686

CCc1cc(=O)c2c(OCC(O)COc3cccc4oc(CO)cc(=O)c34)cccc2o1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GPR35 Q9HC97 2/20 0.60
▸ TDP1 Q9NUW8 2/20 0.60
▸ LMNA P02545 1/20 0.60
▸ MEN1 O00255 5/20 0.58
▸ KMT2A Q03164 5/20 0.58
▸ HIF1A Q16665 1/20 0.58
▸ HPGD P15428 3/20 0.41
▸ ADRB2 P07550 4/20 0.41
▸ NMT2 O60551 2/20 0.41
▸ ADRB1 P08588 2/20 0.41
▸ ADRB3 P13945 2/20 0.41
▸ NMT1 P30419 2/20 0.41
▸ KDM4E B2RXH2 5/20 0.40
▸ ALDH1A1 P00352 4/20 0.40
▸ HSD17B10 Q99714 3/20 0.40
▸ USP2 O75604 1/20 0.40
▸ ATM Q13315 1/20 0.40
▸ BCHE P06276 1/20 0.38
▸ ACHE P22303 1/20 0.38
▸ MAPT P10636 3/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19935419 0.94 GPR35 (0.67) GPR35TDP1LMNAMEN1KMT2A
SCHEMBL25472689 0.89 TDP1 (0.47) GPR35TDP1LMNAMEN1KMT2A
SCHEMBL19925831 0.84 GPR35 (0.64) GPR35TDP1LMNAMEN1KMT2A
SCHEMBL25669932 0.84 GPR35 (0.64) GPR35TDP1LMNAMEN1KMT2A
SCHEMBL19935430 0.83 GPR35 (0.52) GPR35TDP1LMNAMEN1KMT2A
SCHEMBL25669914 0.80 GPR35 (0.50) GPR35TDP1LMNAMEN1KMT2A
SCHEMBL19935517 0.80 GPR35 (0.62) GPR35TDP1LMNAMEN1KMT2A
SCHEMBL24620001 0.80 GPR35 (0.48) GPR35TDP1LMNAMEN1KMT2A
SCHEMBL24600023 0.77 GPR35 (0.58) GPR35TDP1LMNAMEN1KMT2A
SCHEMBL19935421 0.77 GPR35 (0.48) GPR35TDP1LMNAMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230226017-A1 METHODS OF TREATING A CORONAVIRUS INFECTION MASSACHUSETTS GEN HOSPITAL (US) 2023-07-20 — — US disclosed
US-11679095-B2 Macrophages/microglia in neuro-inflammation associated with neurodegenerative diseases THE GENERAL HOSPITAL CORPORATION (US) 2023-06-20 — — US disclosed
US-20230149345-A1 METHODS OF TREATMENT OF CORONAVIRUS-INDUCED INFLAMMATION CONDITIONS THE GENERAL HOSPITAL CORPORATION 2023-05-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11679095-B2 Macrophages/microglia in neuro-inflammation associated with neurodegenerative diseases CD68, PRNP, HTT GPR35 1528/4885TDP1 3376/4885LMNA 755/4885
US-20230149345-A1 METHODS OF TREATMENT OF CORONAVIRUS-INDUCED INFLAMMATION CONDITIONS C3AR1, IL5, C5 GPR35 359/4885TDP1 4796/4885LMNA 3678/4885
US-20230226017-A1 METHODS OF TREATING A CORONAVIRUS INFECTION CPA3, CMA1, ACE2 GPR35 1712/4885TDP1 3569/4885LMNA 2521/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback